Publication

Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of ALKA-372-001, STARTRK-1 and STARTRK-2

Drilon, A
; 
Barlesi, F
; 
De Braud, F
; 
Cho, BC
; 
Ahn, MJ
; 
Siena, S
; 
Krebs, Matthew G
; 
Lin, CC
; 
John, T
; 
Tan, DSW
... show 9 more
Citations
Altmetric:
Abstract
Authors
Drilon, A
Barlesi, F
De Braud, F
Cho, BC
Ahn, MJ
Siena, S
Krebs, Matthew G
Lin, CC
John, T
Tan, DSW
Seto, T
Dziadziuszko, R
Arkenau, HT
Rolfo, C
Wolf, J
Ye, C
Riehl, T
Eng, S
Doebele, RC
Affiliation
Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York,
Description
Date
2019
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Meetings and Proceedings
Citation
Drilon A, Barlesi F, De Braud F, Cho B, Ahn M, Siena S, et al. Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of ALKA-372-001, STARTRK-1 and STARTRK-2. Cancer Res. 2019;79(13).
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/622423
Embedded videos